IL1B and myeloid sarcoma: Accordingly, we demonstrated that blockade of IL-1β activity prevents synaptic hyperexcitability mediated by CSF from gadolinium-positive (Gd1) MS subjects and improves the clinical course of EAE mice (Rossi et al., 2012b; Mandolesi et al., 2013) and that disability progression and excitotoxic-degenerative processes in RR-MS patients likely depends on an enhancement of IL-1β signaling and related regulatory axis (Rossi et al., 2012a,b; Rossi et al., 2014; De Vito et al., 2022).